Uni-Bio Science Group's (HKG:0690) marketing application for the Isavuconazonium Sulfate capsules has been accepted by China's National Medical Products Administration, a Friday Hong Kong bourse filing said.
The drug is an antifungal agent with broad-spectrum antimicrobial activity and is used to treat patients with life-threatening, invasive fungal infections.
The biotechnology company expects the capsules to be approved for launch in the second half of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.